Shannon Grabosch
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Shannon Grabosch has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
- Anda Vlad
Department of OB/Gyn and Reproductive Sciences, University of Pittsburgh, Pittsburgh, PA 15260, USA
3 shared publications - George C. Tseng
Department of Biostatistics, University of Pittsburgh, Pittsburgh, USA
3 shared publications - Amit Lugade
Roswell Park Cancer Institute, Buffalo, NY
2 shared publications - Joan Brozick
Magee-Womens Research Institute, Pittsburgh, PA
2 shared publications - Kunle Odunsi
Roswell Park Comprehensive Cancer Centre (Roswell Park)
2 shared publications - Robert P. Edwards
Department of Gynecologic Oncology, UPMC Magee Women's Hospital, Pittsburgh, PA
2 shared publications
Latest Publications
- 1 August 2018
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 24 (15_Supplem) , B29
Abstract B29: Cisplatin is pro-immunogenic and promotes intrinsic and reactive immune suppression in inflamed and noninflamed ovarian cancer mouse models
Objective: Front-line therapy in ovarian cancer combines platinum/taxane chemotherapy and surgery. We studied here the role of cisplatin on PDL1 biology in vitro and in vivo in new ovarian tumor models. We also explored the in vivo efficacy of PDL1 blockade in combination with cisplatin. Methods: We analyzed in vitro the time and dose dependent effect of cisplatin on PD-L1 expression on human and murine cell lines with varying susceptibility to the drug. Cisplatin-induced molecular changes were detected via unbiased transcriptomics (RNAseq, Illumina). Mechanisms of tumor cell-intrinsic immune resistance were explored in a series of murine ovarian cancer cell lines with defined genetic traits, including conditional mutations in either Kras (activation), Pten (deletion), or both. The effect of cisplatin in combination with PDL1 blockade was tested in vivo in two syngeneic OC models (2F8 and 2F8cis) that mirror platinum sensitive and moderately resistant tumors, respectively. These models have different inflammation at baseline, with 2F8cis tumors being more inflamed (increased tumor-infiltrating lymphocytes [TILs]-increased necrosis) than 2F8 tumors. Results: Exposure of murine and human ovarian cancer cell lines to IC50 cisplatin triggers increased PD-L1 expression in a time- and dose-dependent manner. The effect is partly mediated by Erk/MAPK pathway, as MEK inhibitor AZD6244 inhibits both the baseline and the cisplatin-induced PD-L1 expression. Gene expression analyses (RNASeq) demonstrate that cisplatin upregulates a number of genes that contribute to tumor immunogenicity and increased tumor-reactive CD8 T cells. The cisplatin-induced proinflammatory effect was also observed in vivo, predominantly in platinum-sensitive 2F8 tumors that show increased T-cell infiltration of both CD8 and FoxP3 Tregs. Tumor PDL1 gene expression is also increased upon cisplatin treatment, as detected by qPCR. Mice with platinum-sensitive (2F8) tumors showed increased survival in response to cisplatin alone and anti-PDL1 alone, compared to the combination, which was not significantly different than control treated hosts. In contrast, cisplatin/anti-PDL1 treatment combination triggered significantly longer survival in mice with moderately resistant (2F8cis) tumors. Conclusion: Overall, these results suggest that exposure to cisplatin has the potential to increase tumor immunogenicity and recognition by CD8 TILs while also triggering immune evasion through PD-L1 upregulation either directly (through tumor cell-intrinsic mechanisms) or indirectly via adaptive immune resistance due to IFNγ secreting TILs. Inflamed and noninflamed respond to anti-PD-L1 alone. although the effect is generally modest. Inflamed tumors with moderate platinum resistance respond to cisplatin/anti-PDL1 combination, and the effect is better than for each agent alone. These results provide the rationale for the design of combination therapies that take into consideration tumor inflammation at baseline and drug-induced immunogenic effects. Citation Format: Shannon Grabosch, Mirna Bulatovic, Feitianzhi Zeng, Tianzhou Ma, Lixin Zhang, Malcolm Ross, Joan Brozick, George Tseng, Esther Elishaev, Robert P. Edwards, Anda Vlad. Cisplatin is pro-immunogenic and promotes intrinsic and reactive immune suppression in inflamed and noninflamed ovarian cancer mouse models. [abstract]. In: Proceedings of the AACR Conference: Addressing Critical Questions in Ovarian Cancer Research and Treatment; Oct 1-4, 2017; Pittsburgh, PA. Philadelphia (PA): AACR; Clin Cancer Res 2018;24(15_Suppl):Abstract nr B29.
- 1 August 2018
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 24 (15_Supplem) , B29
Abstract B29: Cisplatin is pro-immunogenic and promotes intrinsic and reactive immune suppression in inflamed and noninflamed ovarian cancer mouse models
Objective: Front-line therapy in ovarian cancer combines platinum/taxane chemotherapy and surgery. We studied here the role of cisplatin on PDL1 biology in vitro and in vivo in new ovarian tumor models. We also explored the in vivo efficacy of PDL1 blockade in combination with cisplatin. Methods: We analyzed in vitro the time and dose dependent effect of cisplatin on PD-L1 expression on human and murine cell lines with varying susceptibility to the drug. Cisplatin-induced molecular changes were detected via unbiased transcriptomics (RNAseq, Illumina). Mechanisms of tumor cell-intrinsic immune resistance were explored in a series of murine ovarian cancer cell lines with defined genetic traits, including conditional mutations in either Kras (activation), Pten (deletion), or both. The effect of cisplatin in combination with PDL1 blockade was tested in vivo in two syngeneic OC models (2F8 and 2F8cis) that mirror platinum sensitive and moderately resistant tumors, respectively. These models have different inflammation at baseline, with 2F8cis tumors being more inflamed (increased tumor-infiltrating lymphocytes [TILs]-increased necrosis) than 2F8 tumors. Results: Exposure of murine and human ovarian cancer cell lines to IC50 cisplatin triggers increased PD-L1 expression in a time- and dose-dependent manner. The effect is partly mediated by Erk/MAPK pathway, as MEK inhibitor AZD6244 inhibits both the baseline and the cisplatin-induced PD-L1 expression. Gene expression analyses (RNASeq) demonstrate that cisplatin upregulates a number of genes that contribute to tumor immunogenicity and increased tumor-reactive CD8 T cells. The cisplatin-induced proinflammatory effect was also observed in vivo, predominantly in platinum-sensitive 2F8 tumors that show increased T-cell infiltration of both CD8 and FoxP3 Tregs. Tumor PDL1 gene expression is also increased upon cisplatin treatment, as detected by qPCR. Mice with platinum-sensitive (2F8) tumors showed increased survival in response to cisplatin alone and anti-PDL1 alone, compared to the combination, which was not significantly different than control treated hosts. In contrast, cisplatin/anti-PDL1 treatment combination triggered significantly longer survival in mice with moderately resistant (2F8cis) tumors. Conclusion: Overall, these results suggest that exposure to cisplatin has the potential to increase tumor immunogenicity and recognition by CD8 TILs while also triggering immune evasion through PD-L1 upregulation either directly (through tumor cell-intrinsic mechanisms) or indirectly via adaptive immune resistance due to IFNγ secreting TILs. Inflamed and noninflamed respond to anti-PD-L1 alone. although the effect is generally modest. Inflamed tumors with moderate platinum resistance respond to cisplatin/anti-PDL1 combination, and the effect is better than for each agent alone. These results provide the rationale for the design of combination therapies that take into consideration tumor inflammation at baseline and drug-induced immunogenic effects. Citation Format: Shannon Grabosch, Mirna Bulatovic, Feitianzhi Zeng, Tianzhou Ma, Lixin Zhang, Malcolm Ross, Joan Brozick, George Tseng, Esther Elishaev, Robert P. Edwards, Anda Vlad. Cisplatin is pro-immunogenic and promotes intrinsic and reactive immune suppression in inflamed and noninflamed ovarian cancer mouse models. [abstract]. In: Proceedings of the AACR Conference: Addressing Critical Questions in Ovarian Cancer Research and Treatment; Oct 1-4, 2017; Pittsburgh, PA. Philadelphia (PA): AACR; Clin Cancer Res 2018;24(15_Suppl):Abstract nr B29.
- 1 August 2018
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 24 (15_Supplem) , B55
Abstract B55: Recurrent transcriptional remodeling events and acquired fusion RNAs in relapsed ovarian cancers
Background: The majority of ovarian cancers (OvCa) are exquisitely sensitive to primary cytoreductive surgery and platinum-based agents, yet up to 80% of late-stage disease will relapse and develop deadly resistance to subsequent therapies. Identifying molecular mediators driving this acquired resistance is essential to improve the tragic 12- to 18-month prognosis for patients with recurrent disease. We hypothesize that relapsed ovarian cancers—which are largely uncharacterized—are molecularly distinct from primary disease and acquire druggable vulnerabilities throughout their life histories. To test this hypothesis, we undertook a transcriptome-wide analysis of 19 longitudinally collected patient-matched pairs of chemotherapy-naïve and recurrent cancers. Materials and Methods: Ilumina TruSeq Total RNA-sequencing was performed on 19 flash-frozen patient-matched pairs of primary and recurrent OvCa. Time to recurrence was up to 64 months with a median of 25 months—a shared variant analysis confirmed all paired samples were patient-matched. Adapter-trimmed RNA-sequencing reads were quantified with k-mer based lightweight-alignment (Salmon v0.8.2) and transcript-abundance estimates were collapsed to gene-level with tximport. Differentially expressed genes were determined with DESeq2 using a paired model to account for patient-matched samples. To identify gains and losses in clinically actionable genes (DGIdb 2.0), pair-specific, outlier fold-change thresholds were defined as Q1/Q3 -/+ [1.5 X IQR], using each pairs’ expression fold-change values (recurrence vs. primary) as the distribution. These discrete, longitudinal transcriptional remodeling events (LTREs) in relapsed OvCa were then assessed for recurrence across all cases. Given that OvCa is thought to be driven largely by genomic structural variation, fusion RNAs were then called with FusionCatcher v0.99.7b. Identified fusions were filtered for cancer specificity by discarding fusions detected in normal tissue (Human Protein Atlas and BodyMap). The same fusion analysis was performed on CCLE OvCa cell line RNA-seq and selected fusions were validated with RT-PCR and Sanger sequencing. Results: A suite of genes were consistently upregulated in OvCa recurrences, the most significant being NTRK2 (adjusted p-value < 0.001)—a targetable tyrosine kinase. LTREs were also common with the most shared LTRE gains in recurrences being INHBA (44%) and IGF1 (39%). 18 of 19 (95%) recurrent cancers acquired cancer-specific fusion RNAs that were undetectable in the primary lesion. An in-frame, recurrence-acquired fusion between TOP2A, a target of doxorubicin and known chemoresistance mediator, and STAU1 was confirmed with RT-PCR. Lastly, we discovered recurrent (2 of 19 cases), in-frame CCDC6-ANK3 fusions that persisted throughout therapy in both the primary and relapsed lesions, each with distinct breakpoints. A CCDC6-ANK3 fusion was also validated in the chemoresistant OVCAR3 cell line. 15 of 19 cases (79%) harbored additional preserved fusions, albeit none were shared between cases. Conclusions: Collectively, these results define multimodal transcriptomic mechanisms of ovarian cancer evolution in late disease. Considering that some acquisitions are highly recurrent and readily druggable (NTRK2, IHBA, IGF1), further preclinical studies are demanded and currently ongoing. Lastly, we establish acquired fusions involving known chemoresistance modulators and preserved fusion transcripts—which are maintained throughout therapy—as common somatic events in OvCa. Because fusion breakpoints are cancer specific, they may serve as promising patient-specific nucleotide targets and biomarkers. Citation Format: Nolan Priedigkeit, Sarah Taylor, Shannon Grabosch, Jahnik Kurukulasuriya, Peter C. Lucas, Silvia Liu, Ester Elishaev, Amit Lugade, Kevin Eng, Anda Vlad, George C. Tseng, Kunle Odunsi, Robert P. Edwards, Adrian V. Lee. Recurrent transcriptional remodeling events and acquired fusion RNAs in relapsed ovarian cancers. [abstract]. In: Proceedings of the AACR Conference: Addressing Critical Questions in Ovarian Cancer Research and Treatment; Oct 1-4, 2017; Pittsburgh, PA. Philadelphia (PA): AACR; Clin Cancer Res 2018;24(15_Suppl):Abstract nr B55.
- 1 August 2018
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 24 (15_Supplem) , B55
Abstract B55: Recurrent transcriptional remodeling events and acquired fusion RNAs in relapsed ovarian cancers
Background: The majority of ovarian cancers (OvCa) are exquisitely sensitive to primary cytoreductive surgery and platinum-based agents, yet up to 80% of late-stage disease will relapse and develop deadly resistance to subsequent therapies. Identifying molecular mediators driving this acquired resistance is essential to improve the tragic 12- to 18-month prognosis for patients with recurrent disease. We hypothesize that relapsed ovarian cancers—which are largely uncharacterized—are molecularly distinct from primary disease and acquire druggable vulnerabilities throughout their life histories. To test this hypothesis, we undertook a transcriptome-wide analysis of 19 longitudinally collected patient-matched pairs of chemotherapy-naïve and recurrent cancers. Materials and Methods: Ilumina TruSeq Total RNA-sequencing was performed on 19 flash-frozen patient-matched pairs of primary and recurrent OvCa. Time to recurrence was up to 64 months with a median of 25 months—a shared variant analysis confirmed all paired samples were patient-matched. Adapter-trimmed RNA-sequencing reads were quantified with k-mer based lightweight-alignment (Salmon v0.8.2) and transcript-abundance estimates were collapsed to gene-level with tximport. Differentially expressed genes were determined with DESeq2 using a paired model to account for patient-matched samples. To identify gains and losses in clinically actionable genes (DGIdb 2.0), pair-specific, outlier fold-change thresholds were defined as Q1/Q3 -/+ [1.5 X IQR], using each pairs’ expression fold-change values (recurrence vs. primary) as the distribution. These discrete, longitudinal transcriptional remodeling events (LTREs) in relapsed OvCa were then assessed for recurrence across all cases. Given that OvCa is thought to be driven largely by genomic structural variation, fusion RNAs were then called with FusionCatcher v0.99.7b. Identified fusions were filtered for cancer specificity by discarding fusions detected in normal tissue (Human Protein Atlas and BodyMap). The same fusion analysis was performed on CCLE OvCa cell line RNA-seq and selected fusions were validated with RT-PCR and Sanger sequencing. Results: A suite of genes were consistently upregulated in OvCa recurrences, the most significant being NTRK2 (adjusted p-value < 0.001)—a targetable tyrosine kinase. LTREs were also common with the most shared LTRE gains in recurrences being INHBA (44%) and IGF1 (39%). 18 of 19 (95%) recurrent cancers acquired cancer-specific fusion RNAs that were undetectable in the primary lesion. An in-frame, recurrence-acquired fusion between TOP2A, a target of doxorubicin and known chemoresistance mediator, and STAU1 was confirmed with RT-PCR. Lastly, we discovered recurrent (2 of 19 cases), in-frame CCDC6-ANK3 fusions that persisted throughout therapy in both the primary and relapsed lesions, each with distinct breakpoints. A CCDC6-ANK3 fusion was also validated in the chemoresistant OVCAR3 cell line. 15 of 19 cases (79%) harbored additional preserved fusions, albeit none were shared between cases. Conclusions: Collectively, these results define multimodal transcriptomic mechanisms of ovarian cancer evolution in late disease. Considering that some acquisitions are highly recurrent and readily druggable (NTRK2, IHBA, IGF1), further preclinical studies are demanded and currently ongoing. Lastly, we establish acquired fusions involving known chemoresistance modulators and preserved fusion transcripts—which are maintained throughout therapy—as common somatic events in OvCa. Because fusion breakpoints are cancer specific, they may serve as promising patient-specific nucleotide targets and biomarkers. Citation Format: Nolan Priedigkeit, Sarah Taylor, Shannon Grabosch, Jahnik Kurukulasuriya, Peter C. Lucas, Silvia Liu, Ester Elishaev, Amit Lugade, Kevin Eng, Anda Vlad, George C. Tseng, Kunle Odunsi, Robert P. Edwards, Adrian V. Lee. Recurrent transcriptional remodeling events and acquired fusion RNAs in relapsed ovarian cancers. [abstract]. In: Proceedings of the AACR Conference: Addressing Critical Questions in Ovarian Cancer Research and Treatment; Oct 1-4, 2017; Pittsburgh, PA. Philadelphia (PA): AACR; Clin Cancer Res 2018;24(15_Suppl):Abstract nr B55.
- 1 July 2017
- Published by Elsevier in Gynecologic Oncology
- Vol. 146 (1) , 137-145
Multiplex profiling identifies distinct local and systemic alterations during intraperitoneal chemotherapy for ovarian cancer: An NRG Oncology/Gynecologic Oncology Group Study
- 1 July 2017
- Published by Elsevier in Gynecologic Oncology
- Vol. 146 (1) , 137-145
Multiplex profiling identifies distinct local and systemic alterations during intraperitoneal chemotherapy for ovarian cancer: An NRG Oncology/Gynecologic Oncology Group Study